Skip to main content
SpringerLink
Log in

The Impact of Prostacyclin Studies on the Development of Its Stable Analogues

  • Conference paper
Prostacyclin and Its Stable Analogue Iloprost

Abstract

The vascular endothelium and, especially, the pulmonary endothelium play the important metabolic role in activation (e.g., angiotensin I) and inactivation (e.g., bradykinin, 5-hydroxytryptamine, catecholamines, nucleotides) of circulating hormones and autacoids [120]. Apart from its metabolic function the endothelium also acts as a generator of two powerful mediators: prostacyclin [34, 84] and endothelium-derived relaxing factor (EDRF) [29]. In contrast with “classical” mediators prostacyclin (t 1/2 = approx 4 min) [12, 34] and EDRF (t 1/2 = approx 6 s) [16, 32] are highly labile. Prostacyclin is one of the products of cyclo-oxygenation of arachidonic acid, while the chemical structure of EDRF remains unknown. Both these mediators are released from the endothelium by similar stimuli, including agonists of muscarinic and serotonin receptors, thrombin, bradykinin and calcium ionophore A 23 187 [36]. Lipid peroxides and oxygen free radicals are the decisive factors in either suppression of the generation or termination of the action of these mediators [34, 37, 121].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Aiken JW, Gorman RR, Shebuski RJ (1979) Prevention of blockage of partially obstructed coronary arteries with prostacyclin correlates with inhibition of platelet aggregation. Prostaglandins 17: 483–494

    Article  PubMed  CAS  Google Scholar 

  2. Armstrong JM, Chappie DJ, Dusting GJ, Hughes R, Moncada S, Vane JR (1978) Cardiovascular actions of prostacyclin in chloralose anesthetized dogs. Br J Pharmacol 62: 125–130

    PubMed  CAS  Google Scholar 

  3. Aust SD, White BC (1985) Iron chelation prevents tissue injury following ischemia. Adv Free Rad Biol Med 1: A1–A17

    Article  Google Scholar 

  4. Balint GA, Varro V (1983) Cytoprotective effect of prostacyclin and protein synthesis. Acta Physiol Hung 61: 115–122

    PubMed  CAS  Google Scholar 

  5. Balint GA, Varro V (1983) Cytoprotection and 6-keto-prostaglandin F1α. Acta Physiol Hung 61: 233–235

    PubMed  CAS  Google Scholar 

  6. Bayer BL, Blass KE, Förster W (1979) Antiaggregatory effect of prostacyclin (PGI2) in vivo. Br J Pharmacol 66: 10–12

    PubMed  CAS  Google Scholar 

  7. Bednar M, Smith B, Pinto A, Mullane KM (1985) Nafazatrom-induced salvage of ischaemic myocardium in anaesthetized dogs is mediated through inhibition of neutrophil function. Circ Res 57: 131–141

    PubMed  CAS  Google Scholar 

  8. Belch JJF, Saniabadi A, Dickson R, Sturrock RD, Forbes CD (1986) Effekt of Iloprost (ZK 36,374) on white cell behaviour. This volume pp 97–102

    Google Scholar 

  9. Blackwell GJ, Radomski M, Vargas JR, Moncada S (1982) Prostacyclin prolongs viability of washed human platelets. Biochim Biophys Acta 718: 60–65

    Article  PubMed  CAS  Google Scholar 

  10. Boullin DJ, Bunting S, Blaso WP, Hunt TM, Moncada S (1979) Response of human and baboon arteries to prostaglandin endoperoxide and biologically generated and synthetic prostacyclin: their relevance to arterial cerebral spasm in man. Br J Clin Pharmacol 7: 139–147

    PubMed  CAS  Google Scholar 

  11. Brandt RR, Dembinska-Kieć A, Korbut R, Gryglewski RJ, Nowak J (1984) Release of prostacyclin from the human pulmonary vascular bed in response to colinergic stimulation. Naunyn-Schmiedebergs Arch Pharmacol 325: 69–75

    Article  PubMed  CAS  Google Scholar 

  12. Bunting S, Gryglewski RJ, Moncada S, Vane JR (1976) Arterial walls generate from prostaglandin endoperoxides a substance (Prostaglandin X) which relaxes strips of mesenteric and coeliac arteries and inhibits platelet aggregation. Prostaglandins 12: 897–915

    Article  PubMed  CAS  Google Scholar 

  13. Bursch W, Schulte-Hermann R (1986) Cytoprotective effect of Iloprost against liver cell death induced by carbon tetrachloride (CCL4) or bromobenzene. This volume pp 257–268

    Google Scholar 

  14. Bussolino S, Camussi G (1980) Effect of prostacyclin on platelet activating factor-induced platelet aggregation. Prostaglandins 20: 781–791

    Article  PubMed  CAS  Google Scholar 

  15. Coceani F, Bishai J, White E, Badach E, Olley PM (1978) Action of prostaglandin endoperoxides and thromboxanes on the lamb ductus arteriosus. Am J Physiol 234: 1117–1121

    Google Scholar 

  16. Cocks TM, Angus JA, Campbell JH, Cambell GR (1985) Release and properties of endothelium-derived relaxing factor (EDRF) from endothelial cells in culture. J Cell Physiol 123: 310–320

    Article  PubMed  CAS  Google Scholar 

  17. Colli S, Lomeroso M, Maderna P, Tremoli E, Nicosia S (1983) Effects of PGI2 on platelet aggregation and adenylate cyclase activity in human type IIa hypercholesterolemia. Biochem Pharmacol 32: 1989–1993

    Article  PubMed  CAS  Google Scholar 

  18. Crutchley DJ, Conanan LB, Maynard JR (1982) Stimulation of fibrinolytic activity in human skin fibroblasts by prostaglandin El, E2 and E2. J Pharmacol Exp Ther 222: 544–547

    PubMed  CAS  Google Scholar 

  19. Dembinska-Kieć A, Kostka-Trabka E, Grodzinska L, Kedzior A, Telesz E, Gryglewski RJ (1983) Fibrinolytic activity of prostacyclin in humans with thromboembolic disorders. Zentralbl Pharmacol 122: 746–749

    Google Scholar 

  20. Dembinska-Kieć, Kostka-Trabka E, Gryglewski RJ (1982) Effect of prostacyclin on fibrinolytic activity in patients with arteriosclerosis obliterans. Thromb Haemost 47: 190

    PubMed  Google Scholar 

  21. Dembinska-Kieć A, Rucker W, Schonhofer PS (1980) Effects of PGI2 and PGI2 analogues on cAMP levels in cultured endothelial and smooth muscle cells derived from bovine arteries. Naunyn-Schmiedebergs Arch Pharmacol 311: 67–70

    Article  PubMed  Google Scholar 

  22. Dusting GJ, Chappie DJ, Hughes R, Moncada S, Vane JR (1978) Prostacyclin induces coronary vasodilatation in anaesthetized dogs. Cardiovasc Res 12: 720–730

    Article  PubMed  CAS  Google Scholar 

  23. Dusting GJ, Moncada S, Vane JR (1977) Prostacyclin (PGX) is the endogenous metabolite responsible for relaxation of coronary arteries induced by arachidonic acid. Prostaglandins 13: 3–15

    Article  PubMed  CAS  Google Scholar 

  24. Ehrmann HL, Jaffe EA (1980) Prostacyclin (PGI2) inhibits the development in human platelets of ADP and arachidonic acid-induced shape change and pro-coagulant activity. Prostaglandins 20: 1103–1116

    Article  Google Scholar 

  25. Eldor A, Weksler BB (1979) Heparin and dextrane sulphate antagonise PGI2 inhibition of platelet aggregation. Thromb Res 16: 617–628

    Article  PubMed  CAS  Google Scholar 

  26. Fantone J, Kinnes DA (1983) Prostaglandion E1 and prostaglandin I2 modulation of superoxide production by human neutrophils. Biochem Biophys Res Commun 113: 506–512

    Article  PubMed  CAS  Google Scholar 

  27. Fletcher JR, Ramwell PW (1979) Comparison of the cardiovascular effects of prostacyclin with those of prostaglandin E2 in the Rhesus monkey. In: Vane, Bergstrom (eds) Prostacyclin. Raven, New York p 259

    Google Scholar 

  28. Fry GL, Czervionke RL, Hoak JC, Smith JB, Haycraft PL (1980) Platelet adherence to cultured vascular cells: influence of prostacyclin (PGI2). Blood 55: 271–285

    PubMed  CAS  Google Scholar 

  29. Furchgott RF, Zawadzki J (1980) The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 288: 373–376

    Article  PubMed  CAS  Google Scholar 

  30. Gardner TJ, Stewart JR, Casale AS, Downey JM, Chambers DE (1983) Reduction of myocardial ischemic injury with oxygen-derived free radical scavengers. Surgery 94: 423–427

    PubMed  CAS  Google Scholar 

  31. Gorman RR, Bunting S, Miller OV (1977) Modulation of human platelet adenylate cyclase by prostacyclin (PGX). Prostaglandins 13: 377–388

    Article  PubMed  CAS  Google Scholar 

  32. Griffith TM, Edwards DH, Lewis MJ, Newby AC, Henderson AH (1984) The nature of endothelium-derived vascular relaxant factor. Nature 308: 645–647

    Article  PubMed  CAS  Google Scholar 

  33. Grodzinska K, Basista M, Kedzior A, Korbut R, Kostka-Trabka E, Gryglewski RJ (1983) Fibrinolytic activity of beta-piridylcarbinol (Ronicol) in patients with arteriosclerosis obliterans. Thromb Haemost 50: 797–799

    PubMed  CAS  Google Scholar 

  34. Gryglewski RJ, Bunting S, Moncada S, Flower RJ, Vane JR (1976) Arterial walls are protected against deposition of platelet thrombi by a substance which they make from prostaglandin endoperoxides. Prostaglandins 12: 685–713

    Article  PubMed  CAS  Google Scholar 

  35. Gryglewski RJ, Korbut R, Ocetkiewicz A (1978) Generation of prostacyclin by lungs in vivo and its release into the arterial circulation. Nature 273: 765–767

    Article  PubMed  CAS  Google Scholar 

  36. Gryglewski RJ, Moncada S, Palmer RMJ (1986) Bioassay of prostacyclin and endothelium-derived relaxing factor ( EDRF) from porcine aortic endothelial cells. Br J Pharmacol (to be published )

    Google Scholar 

  37. Gryglewski RJ, Palmer R, Moncada S (1986) Superoxide anion plays a role in the break-down of endothelium-derived relaxing factor (to be published )

    Google Scholar 

  38. Gryglewski RJ, Szczeklik A, McGiff JC (eds) (1985) Prostacyclin — clinical trials. Raven, New York, pp 1–143

    Google Scholar 

  39. Gryglewski RJ, Szczeklik A, Niźankowski R (1978) Antiplatelet action of intravenous in-fusion of prostacyclin in man. Thromb Res 13: 153–163

    Article  PubMed  CAS  Google Scholar 

  40. Hadhazy P, Malmovölgyi B, Magyar K (1984) Differential contractile responsiveness of isolated rabbit arteries from different vascular beds to cyclo-oxygenase inhibitors and PGI2. Eur J Pharmacol 98: 323–330

    Article  PubMed  CAS  Google Scholar 

  41. Hallenbeck JM (1985) Effect of prostacyclin, indomethacin and heparin on postischemic nerve cell function. In: Gryglewski, Szczeklik, McGiff (eds) Prostacyclin — clinical trials. Raven, New York, pp 83–93

    Google Scholar 

  42. Ham EA, Soderman DD, Zanetti ME, Dougherty HW, McCauley E, Kuehl F (1983) Inhibition by prostaglandins of leukotriene release from activated neutrophils. Proc Natl Acad Sci USA 80: 4349–4353

    Article  PubMed  CAS  Google Scholar 

  43. Hawiger J, Parkinson S, Timmons S (1980) Prostacyclin inhibits mobilisation of fibrinogen-binding sites on human ADP and thrombin-treated platelets. Nature 283: 195–198

    Article  PubMed  CAS  Google Scholar 

  44. Herbaczynska-Cedro K, Gordon-Majszak W (1986) Attenuation by prostacyclin of adrenalin-stimulated lipid peroxidation in the myocardium (to be published)

    Google Scholar 

  45. Higgs GA (1982) Prostaglandins and the microcirculation. In: Herman, Vanhoutte, Denolin, Goosens (eds) Cardiovascular pharmacology of prostaglandins. Raven, New York, pp 315–324

    Google Scholar 

  46. Higgs EA, Higgs GA, Moncada S, Vane JR (1978) Prostacyclin (PGI2) inhibits the formation of platelet thrombi in arterioles and venules of the hamster cheek pouch. Br J Pharmacol 63: 535–539

    PubMed  CAS  Google Scholar 

  47. Higgs EA, Moncada S, Vane JR (1977) Effect of prostacyclin (PGI2) on platelet adhesion to rabbit arterial subendothelium. Prostaglandins 16: 17–22

    Article  Google Scholar 

  48. Hintze TH, Kaley G, Martin EH, Messina EJ(1978) PGI2 induces bradycardia in the dog. Prostaglandins 15: 712

    Google Scholar 

  49. Hock CE, Phillips GR, Lefer AM (1985) Protective action of a thromboxane synthetase inhibitor in preventing extension of infarct size in acute myocardial infarction. Prostaglandins Leukotrienes Med 17: 339–346

    Article  CAS  Google Scholar 

  50. Ito TT, Ogawa K, Enomoto J, Hasimoto H, Kai J, Satake T (1980) Comparison of effects of PGI2 and PGE1 on coronary and systemic hemodynamics and on coronary arterial cyclic nucleotide levels in dogs. In: Samuelsson, Ramwell, Paoletti (eds) Advan Prostaglandin Thromboxane Leukotriene Res 7: 641–646

    Google Scholar 

  51. Johansson C, Bergström S (1982) Prostaglandins and protection of the gastroduodenal mucosa. Scand J Gastroenterol 17: 21–46

    Article  CAS  Google Scholar 

  52. Jolly SR, Kane WJ, Baillie MB, Abrams GD, Lucchesi BR (1984) Canine myocardial reperfusion injury: its reduction by the combined administration of superoxide dismutase and catalose. Circ Res 54: 277–285

    PubMed  CAS  Google Scholar 

  53. Jolly SR, Schumacher WA, Kunkel SW, Abrams GD, Liddicoat J, Lucchesi BR (1985) Platelet depletion in experimental myocardial infarction. Basic Res Cardiol 80: 269–279

    Article  PubMed  CAS  Google Scholar 

  54. Jugdutt BJ (1985) Delayed effects of early infarct-limiting therapies on healing after myocardial infarction. Circulation 72: 907–914

    Article  PubMed  CAS  Google Scholar 

  55. Jugdutt BJ, Hutchins GM, Bulkley BH, Becker LC (1981) Dissimilar effects of prostacyclin, prostaglandin E1 and prostaglandin E2 on myocardial infarct size after coronary occlusion in conscious dogs. Circ Res 49: 685–700

    PubMed  CAS  Google Scholar 

  56. Kadowitz PJ, Chapnic BM, Feigen LP, Hyman AL, Nelson PK, Spannhake EW (1978) Pulmonary and systemic vasodilatory effects of the newly discovered prostaglandin PGI2. J Appl Physiol 45: 408–413

    PubMed  CAS  Google Scholar 

  57. Kadowitz PJ, Shee SS, McNamara DB, Spannhake EW, Hyman AL (1982) Arachidonic acid transformation in the lung. In: Herman AG, Vanhoutte PM, Denolin H, Goosens A (eds) Cardiovascular pharmacology of prostaglandins. Raven, New York, p 287

    Google Scholar 

  58. Karniguaian A, Legrand JP, Caen JP (1982) Prostaglandins: specific inhibition of platelet adhesion to collagen and relationship with cAMP level. Prostaglandins 23: 437–457

    Article  Google Scholar 

  59. Konturek SJ (1982) Gastric cytoprotection. Mt Sinai J Med 49: 355–369

    PubMed  CAS  Google Scholar 

  60. Konturek SJ, Robert A (1982) Cytoprotection of canine gastric mucosa by prostacyclin: possible mediation by increased mucosal blood flow. Digestion 25: 155–163

    Article  PubMed  CAS  Google Scholar 

  61. Korbut R, Byrska-Danek A, Gryglewski RJ (1983) Fibrinolytic activity of 6-keto-prostaglandin E1 Thromb Haemost 50: 893

    PubMed  CAS  Google Scholar 

  62. Lefer AM, Ogletree MNL, Smith JB, Silver MJ, Nicolaou KC, Barnette WE, Gasic GP (1978) Prostacyclin: a potentially valuable agent for preserving myocardial tissue in acute myocardial ischaemia. Science 200: 52–54

    Article  PubMed  CAS  Google Scholar 

  63. Leigh PJ, Cramp WA, MacDermot J (1984) Identification of the prostacyclin receptor by radiation inactivation. J Biol Chem 259: 12431–12436

    PubMed  CAS  Google Scholar 

  64. Levy SV (1978) Contractile responses to prostacyclin (PGI2) of isolated human saphenous and rat venous tissue. Prostaglandins 16: 93–97

    Article  PubMed  CAS  Google Scholar 

  65. Leytin VL, Sviridov DD (1982) A model for studying platelet interaction with cellular and macromolecular constituents of the vessel wall in vitro. In: Chazov EI, Smirnov VN (eds) Vessel wall in athero- and thrombogenesis. Studies in USSR. Springer, Berlin Heidelberg New York, p 173

    Google Scholar 

  66. Lijnen HR, Collen D (1984) Molecular mechanism of fibrinolysis. In: Strano A (ed) Thrombosis and cardiovascular disease. Plenum, New York, p 217

    Google Scholar 

  67. Lucchesi BR (1985) Leukocytes and leukocyte-derived products in myocardial ischemic injury. In: Schrör K (ed) Prostaglandins and other eicosanoids in the cardiovascular system. Karger, Basel, p 160

    Google Scholar 

  68. Maclntyre DE, Gordoy JL (1977) Discrimination between platelet prostaglandin receptors with a specific antagonist of bisenoic prostaglandins. Thromb Res 11: 705

    Article  Google Scholar 

  69. McCord JM (1985) Oxygen-derived free radicals in postischemic tissue injury. In: Epstein FH (ed) Mechanism of disease. N Engl J Med 312: 159–163

    Google Scholar 

  70. Mehta K, Metha P, Cont CR (1980) Platelet function studies in coronary heart disease. IX. Increased platelet prostaglandin generation and abnormal platelet sensitivity to prostacyclin and endoperoxide analog in angina pectoris. Am J Cardiol 48: 943–947

    Article  Google Scholar 

  71. Melin JA, Becker LC (1983) Salvage of ischaemic myocardium by prostacyclin during experimental myocardial infarction. J Am Coll Cardiol 2: 279–286

    Article  PubMed  CAS  Google Scholar 

  72. Messina EJ, Kaley G (1980) Microcirculatory responses to prostacyclin and prostaglandin E2 in rat cremaster muscle. In: Samuelsson B, Ramwell P, Paoletti R (eds) Advances in prostaglandin and thromboxane research, vol 7. Raven, New York, p 719

    Google Scholar 

  73. Miller OV, Gorman RR (1979) Evidence for distinct prostaglandin I2 and D2 receptors in human platelets., J Pharmacol Exp Ther 210: 134–140

    PubMed  CAS  Google Scholar 

  74. Moncada S, Gryglewski RJ, Bunting S, Vane JR (1976) An enzyme transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 263: 663–665

    Article  PubMed  CAS  Google Scholar 

  75. Mozsik G, Moron F, Javor T (1982) Cellular mechanism of the development of gastric mucosal damage and gastrocytoprotection induced by prostacyclin in rats. A pharmacological study. Prostaglandins Leukotrienes Med 9: 71–84

    Article  CAS  Google Scholar 

  76. Musial J, Wilczynska M, Sladek K, Cierniawski CS, Nizankowski R, Szczeklik A (1986) Fibrinolytic activity of prostacyclin and Iloprost in patients with peripheral arterial disease. Prostaglandins (to be published)

    Google Scholar 

  77. Myers ML, Bolli R, Lekich RF, Hartley CJ, Roberts R (1985) Enhancement of recovery of myocardial function by oxygen free radical scavengers after reversible regional ischemia. Circulation 72: 915–921

    Article  PubMed  CAS  Google Scholar 

  78. Nickolson RC, Town MH, Vorbrüggen H (1985) Prostacyclin — analogs. Med Res Rev 5: 1–53

    Article  PubMed  CAS  Google Scholar 

  79. O’Grady J, Warington S, Moti J et al. (1980) Effect of intravenous infusion of prostacyclin in man. Prostaglandins 19: 319–332

    Article  PubMed  Google Scholar 

  80. Opie LH (1979) Energy metabolism of heart muscle during hypoxia and ischemia. In: Gross (ed) Modulation of sympathetic tone in treatment of cardiovascular disease. Huber, Bern, pp 43–53

    Google Scholar 

  81. Pannochia A, Hardisty RM (1985) Cyclic AMP inhibits platelet activation independently of its effects on cytosolic free calcium. Biochem Biophys Res Commun 127: 339–345

    Article  Google Scholar 

  82. Peskar BA (1986) Personal communication

    Google Scholar 

  83. Rapaport RM, Draznin MB, Murad F (1983) Endothelium-dependent relaxation in rat aorta may be mediated through cyclic GMP-dependent protein phosphorylation. Nature 306: 174–176

    Article  Google Scholar 

  84. Rebert HA, Tweedie JH, Mosley JG (1980) The cytoprotective effect of 16,16-dimethyl prostaglandin E2 on bile induced damage to the pancreas. Gastroenterology 78: 1241–1247

    Google Scholar 

  85. Renkawek K, Herbaczynska-Cedro K, Mossakowski MJ (1986) The effect of prostacyclin on morphological and enzymatic properties of CNS cultures exposed to annoxia. Acta Neurol Scand (to be published)

    Google Scholar 

  86. Robert A (1976) Antisecretory, antiulcer, cytoprotective and diarrheogenic properties of prostaglandins. In: Samuelsson, Paoletti (eds) Adv Prostaglandin Thromboxane Res 2: 507–520

    Google Scholar 

  87. Robert A (1984) On the mechanism of cytoprotection by prostaglandins. Ann Clin Res 16: 335–338

    PubMed  CAS  Google Scholar 

  88. Romson JL, Hack DW, Abrams GD, Lucchesi BR (1981) Prevention of occlusive coronary artery thrombosis by prostacyclin infusion in the dog. Circulation 64: 906–914

    Article  PubMed  CAS  Google Scholar 

  89. Romson JL, Hook BG, Lucchesi BR (1983) Potentiation of the antithrombotic effect of prostacyclin by simultaneous administration of aminophylline in a canine model of coronary artery thrombosis. J Pharmacol Exp Ther 227: 288–294

    PubMed  CAS  Google Scholar 

  90. Ruwart MJ, Nichols NM, Rush BD, Mochizuki R, Elliot G, Brunden MN (1985) 16,16-dimethyl PGE2 partially prevents N-phenylanthranilic acid-induced kidney damage in the rat. Prostaglandins Leukotrienes Med 20: 139–140

    Google Scholar 

  91. Ruwart MJ, Rush BD, Friedle NM, Piper RC, Kolaja GJ (1981) Protective effects of 16,16-dimethyl PGE2 on the liver and kidney. Prostaglandins [Suppl] 21: 97–102

    Article  PubMed  CAS  Google Scholar 

  92. Saba HI, Saba SR, Blackburn CA, Hartmann RC, Mason RG (1979) Heparin neutralization of PGI2: effects upon platelets. Science 205: 499–501

    Article  PubMed  CAS  Google Scholar 

  93. Saito S, Tamura Y, Tsuzi M et al. (1983) Coronary vasodilatory effects of prostacyclin in patients with ischemic heart disease. Nihon Univ J Med 25: 241–250

    Google Scholar 

  94. Schrör K, Addicks K, Darius H, Ohlendorf R, Rosen P (1981) PGI2 inhibits ischemia induced platelet activation and prevents myocardial damage by inhibition of catecholamine release from adrenergic nerve terminals. Evidence for cAMP as common denominator. Thromb Res 21: 175–180

    Google Scholar 

  95. Schrör K, Darius H, Ohlender R, Matzky R, Klaus W (1982) Dissociation of antiplatelet effects from myocardial cytoprotective activity during acute myocardial ischemia in cats by a new carbocyclin derivative (ZK 36375). J Cardiovasc Pharmacol 4: 554–561

    PubMed  Google Scholar 

  96. Schumacher WA, Lee EC, Lucchesi BR (1985) Augmentation of streptokinase thrombolysis by heparin and prostacyclin. J Cardiovasc Pharmacol 7: 739–766

    Article  PubMed  CAS  Google Scholar 

  97. Shlafer M, Kane PF, Wiggins S, Kirsh MM (1982) Possible role for cytotoxic oxygen metabolites in the pathogenesis of cardiac ischemic injury. Circulation 66: 85–92

    CAS  Google Scholar 

  98. Simpson PJ, Lucchesi BR (1986) Myocardial ischemia: the potential therapeutic role of prostacyclin and its analogues. This volume pp 179–194

    Google Scholar 

  99. Sintetos AL, Bogler PM, Ramwell PW (1979) Effects of prostacyclin on isolated canine renal artery and vein. In: Vane, Bergström (eds) Prostacyclin. Raven, New York, p 269

    Google Scholar 

  100. Sinzinger H, Silberbauer K, Horsch AK, Gall A (1981) Decreased sensitivity of human platelets to PGI2 during long-term intraarterial prostacyclin infusion in patients with peripheral vascular disease — a rebound phenomenon. Prostaglandins 21: 49–51

    Article  PubMed  CAS  Google Scholar 

  101. Stachura J, Kaluza J (1982) Influence of prostaglandin on actinomycin C-induced degeneration of embryonal neurodermal tissue. Prostaglandins 24: 433–439

    Article  PubMed  CAS  Google Scholar 

  102. Stachura J, Tarnawski A, Ivey KJ, Mach T, Bogdal J, Szczudrawa J, Klimczyk B (1981) Prostaglandin protection of carbon tetrachloride-induced liver cell necrosis in the rat. Gastroenterology 81: 212–217

    Google Scholar 

  103. Stam H, Koster JF (1985) Fatty acid peroxidation in ischemia. In: Schrör (ed) Prostaglandins and other eicosanoids in the cardiovascular system. Karger, Basel, pp 131–148

    Google Scholar 

  104. Stewart JR, Blackwell WH, Crute SL, Loughlin V, Hess ML, Greenfield LJ (1982) Prevention of myocardial ischaemia/reperfusion injury with oxygen free-radical scavengers. Surg Forum 33: 317–320

    Google Scholar 

  105. Stürzebecher C, Haberey M, Müller B, Schillinger E, Schröder G, Skuballa W, Stock G (1985) Pharmacological profile of ZK 96480, a new chemically and metabolically stable prostacyclin analogue with oral availability and high PGI2 intrinsic activity. In: Schrör (ed) Prostaglandins and other eicosanoids in cardiovascular system. Karger, Basel, pp 485–491

    Google Scholar 

  106. Stürzebecher CS, Losert W (1986) Effects of Iloprost on platelet aggregation in vitro. This volume pp 39–45

    Google Scholar 

  107. Szekeres L, Krassoi J, Pataricza J, Udvary E (1984) Delayed antiischemic effect of prostaglandin I2 and a new stable prostaglandin I2 analogue, 7-oxo-prostacyclin-Na, in experimental model of angina in dogs. In: Advances in Myocardiology, vol 6. Plenum, New York, pp 607–618

    Google Scholar 

  108. Szczeklik A, Gryglewski RJ (1979) Action of prostacyclin in man. In: Vane, Bergström (eds) Prostacyclin. Raven, New York, p 393

    Google Scholar 

  109. Szczeklik A, Kopec M, Sladek K, Musial J, Chmielewska J, Teisseyre E, Dudek-Wojciechowska E, Palester-Chlebowczyk M (1983) Prostacyclin and the fibrinolytic system in ischaemic vascular disease. Thromb Res 29: 655–660

    Article  PubMed  CAS  Google Scholar 

  110. Szczeklik A, Musial (1985) Platelets and ischaemic heart disease. In: The platelets: physiology and pharmacology. Academic, New York, pp 407–428

    Google Scholar 

  111. Szczeklik J, Szczeklik A, Nizankowski R (1980) Prostacyclin for pulmonary hypertension. Lancet 2: 1076

    Article  PubMed  CAS  Google Scholar 

  112. Szczeklik J, Szczeklik A, Nizankowski R (1980) Haemodynamic changes induced by prostacyclin in man. Br Heart J 44: 254–260

    Article  PubMed  CAS  Google Scholar 

  113. Tateson JE, Moneada S, Vane JR (1977) Effects of prostacyclin (PGX) on cyclic AMP concentrations in human platelets. Prostaglandins 13: 289–397

    Article  Google Scholar 

  114. Tepperman BL, Soper BD, Emery S (1984) Specific binding of a stable prostacyclin analogue (Iloprost) to rat oxyntic mucosa. Prostaglandins 28: 477–484

    Article  PubMed  CAS  Google Scholar 

  115. Thiemermann C, Steinhagen-Thiessen E, Schrör K (1984) Inhibition of oxygen centered free-radical formation by the stable prostacyclin-mimetic Iloprost (ZK 36 374) in acute myocardial ischemia. J Cardiovasc Pharmacol 6: 365–366

    Article  PubMed  CAS  Google Scholar 

  116. Ubatuba FB, Moneada S, Vane JR (1979) The effect of prostacyclin (PGI2) on platelet behaviour, thrombus formation in vivo and bleeding time. Thromb Haemost 41: 425–434

    PubMed  CAS  Google Scholar 

  117. Uchida Y, Murao S (1979) Effect of prostaglandin I2 on cyclical reductions of coronary blood flow. Jpn Circ J 43: 645–652

    Article  PubMed  CAS  Google Scholar 

  118. Uchida Y, Murao S (1981) Role of prostaglandin I2 and thromboxane A2 in recurring reduction of carotid and cerebral flow in dogs. Stroke 12: 786–792

    Article  PubMed  CAS  Google Scholar 

  119. Utsunomiya T, Krausz MM, Valeri GR, Shepro D, Hechtman HB (1980) Treatment of pulmonary embolism with prostacyclin. Surgery 88: 25–30

    PubMed  CAS  Google Scholar 

  120. Vane JR (1969) The release and fate of vasoactive hormones in the circulation. Br J Pharmacol 35: 209–242

    PubMed  CAS  Google Scholar 

  121. Vanhoutte PM, Houston DS (1985) Platelets, endothelium and vasospasm. Circulation 72: 728–734

    Article  PubMed  CAS  Google Scholar 

  122. Whittle BJR, Kaufmann GL, Boughton-Smith NK (1984) Stimulation of gastric alkaline secretion by stable prostacyclin analogues in rat and dog. Eur J Pharmacol 100: 277–283

    Article  PubMed  CAS  Google Scholar 

  123. Whittle BJR, Moncada S (1984) Antithrombotic assessment and clinical potential of prostacyclin analogues. In: Ellis, West (eds) Progress in medicinal chemistry. Elsevier, Amsterdam, pp 238–279

    Google Scholar 

  124. Whittle BJR, Moncada S, Vane JR (1978) Comparison of the effects of prostacyclin, prostaglandin E1 and D2 on platelet aggregation of different species. Prostaglandins 16: 373–388

    Article  PubMed  CAS  Google Scholar 

  125. Williams PB, Joyner JH (1982) Response of peripheral collateral arteries in the dog to prostaglandins E1, E2, F2α and I2(prostacyclin). J Cardiovasc Pharmacol 4: 784–790

    Article  PubMed  CAS  Google Scholar 

  126. Witt W, Baldus B, Müller B (1986) Antithrombotic profile of Iloprost in experimental models of arterial and venous thrombosis. This volume pp 81–90

    Google Scholar 

  127. Werns SW, Shea MJ, Driscoll EM, Cohen C, Abrams GD, Pitt B, Lucchesi BR (1985) The independent effects of oxygen radical scavengers on canine infarct size. Reduction by super-oxide dismutase and not atalase. Circ Res 56: 895–898

    PubMed  CAS  Google Scholar 

  128. Wong PYK, Pieroni JP, McGiff JC (1985) 6-keto-prostaglandin E1:biosynthesis and function. In: Gryglewski, Szczeklik, McGiff (eds) Prostacyclin — clinical trials. Raven, New York, pp 125–137

    Google Scholar 

  129. Zygulska-Mach H, Kostka-Trabka E, Grodzinska L, Bieron K, Telesz E, Gryglewski RJ (1985) Prostacyclin in the therapy of central retinal vein occlusion. In: Gryglewski, Szczeklik, McGiff (eds) Prostacyclin — clinical trials. Raven, New York, pp 67–75

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacology, N. Copernicus Academy of Medicine in Cracow, Poland

    R. J. Gryglewski

Authors
  1. R. J. Gryglewski
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Pharmacology, Copernicus Academy of Medicine, 16 Grzegórzecka, 31531, Cracow, Poland

    R. J. Gryglewski

  2. Cardiovascular Pharmacology, Schering AG, Müllerstraße 170–178, 1000, Berlin 65, Germany

    G. Stock

Rights and permissions

Reprints and permissions

Copyright information

© 1987 Springer-Verlag, Berlin Heidelberg

About this paper

Cite this paper

Gryglewski, R.J. (1987). The Impact of Prostacyclin Studies on the Development of Its Stable Analogues. In: Gryglewski, R.J., Stock, G. (eds) Prostacyclin and Its Stable Analogue Iloprost. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-71499-3_1

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-71499-3_1

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-71501-3

  • Online ISBN: 978-3-642-71499-3

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation